Abstract:TYK2 mediates signaling of IL-23, IL-12, and Type I IFN-driven responses that are critical in immune-mediated diseases. Herein, we report the design, synthesis, and structure–activity relationships (SARs) of 3-(4-(2-((1H-indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile derivatives as selective TYK2 inhibitors. Among them, compound 14l exhibited acceptable TYK2 inhibition with an IC50 value of 9 nM, showed satisfactory selectivity characteristics over the other three homologous JAK kinases, and performed good functional potency in the JAK/STAT signaling pathway on lymphocyte lines and human whole blood. In liver microsomal assay studies, the clearance rate and half-life of 14l were 11.4 mL/min/g and 121.6 min, respectively. Furthermore, in a dextran sulfate sodium colitis model, 14l reduced the production of pro-inflammatory cytokines IL-6 and TNF-α and improved the inflammation symptoms of mucosal infiltration, thickening, and edema. Taken together, 14l was a selective TYK2 inhibitor and could be used to treat immune diseases deserving further investigation.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01468?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01468</a>.11e_in_2XA4_JAK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_001.pdb">PDB</a>)11e_in_4GJ3_TYK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_002.pdb">PDB</a>)14l_in_2XA4_JAK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_003.pdb">PDB</a>)14l_in_4GJ3_TYK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_004.pdb">PDB</a>)jmcmar_ccc (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_005.xls">XLS</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_006.csv">CSV</a>)Compounds 12a–12g with different hinge binders and their enzymatic potencies (Table S1); enzymatic potencies and the metabolic stability of compounds 13a–13l (Table S2); enzymatic potencies and the metabolic stability of compounds 14a–14o (Table S3); kinome-wide selectivity profiling of compound 14l @ 0.1 μM (Table S4); 1H NMR, 13C NMR, and HRMS-ESI of 14l, respectively (Figures S1–S3); purity of 14l (Figure S4); and biological assay methods (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_007.pdf">PDF</a>)This article has not yet been cited by other publications.

Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors.

Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors

Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2

Design and synthesis of triazolopyridine derivatives as potent JAK/HDAC dual inhibitors with broad-spectrum antiproliferative activity

Structure‐guided design of potent JAK1‐selective inhibitors based on 4‐amino‐7H‐pyrrolo[2,3‐d]pyrimidine with anti‐inflammatory efficacy

Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease

Computational insights into rational design and virtual screening of pyrazolopyrimidine derivatives targeting Janus kinase 3 (JAK3)

Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor

Structural optimizations on the 7H-pyrrolo[2,3-d]pyrimidine scaffold to develop highly selective, safe and potent JAK3 inhibitors for the treatment of Rheumatoid arthritis

Discovery of furopyridine-based compounds as novel inhibitors of Janus kinase 2: In silico and in vitro studies

Discovery of 4-Aminoquinoline-3-carboxamide Derivatives As Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis

Design, synthesis and biological evaluation of purine-based derivatives as novel JAK2/BRD4(BD2) dual target inhibitors

In silico discovery of potent and selective Janus kinase 3 (JAK3) inhibitors through 3D-QSAR, covalent docking, ADMET analysis, molecular dynamics simulations, and binding free energy of pyrazolopyrimidine derivatives

Design and synthesis of highly selective Janus kinase 3 covalent inhibitors for the treatment of rheumatoid arthritis

Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3)

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Discovery of Hexahydrofuro[3,2- b ]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant

Revealing innovative JAK1 and JAK3 inhibitors: a comprehensive study utilizing QSAR, 3D-Pharmacophore screening, molecular docking, molecular dynamics, and MM/GBSA analyses

Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors.

Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives As Potent and Selective FGFR Kinase Inhibitors.

Discovery of 3-(4-(2-((1 H -Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1 H -pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease